Pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.

Regulatory News:

Median Technologies (Paris:ALMDT):

Total number of shares

18,448,233

Number of real voting rights*

(excluding treasury shares**)

18,389,711

Theoretical number of voting rights*

(including treasury shares**)

18,425,033

(*) Class E preference shares are non-voting

(**) pursuant to article 223-11 of the AMF’s General Regulations

About Median Technologies: Pioneering innovative imaging solutions and services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as medical devices (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.

Median Technologies Emmanuelle Leygues Head of Corporate Marketing & Financial Communications +33 6 10 93 58 88 emmanuelle.leygues@mediantechnologies.com

Press - ALIZE RP Caroline Carmagnol +33 6 64 18 99 59 median@alizerp.com

Investors - ACTIFIN Ghislaine Gasparetto +33 6 21 10 49 24 ghislaine.gasparetto@seitosei-actifin.com

Median Technologies (EU:ALMDT)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024 Haga Click aquí para más Gráficas Median Technologies.
Median Technologies (EU:ALMDT)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024 Haga Click aquí para más Gráficas Median Technologies.